摘要
Background: Chronic Graft-versus-Host Disease (cGvHD) occurs in 30-70% of patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and is caused by an immune-mediated response of the donor-derived T cells against recipient tissues.Vulvovaginal chronic GvHD (vv-cGvHD) incidence ranges from 7 to 69%.Main signs and symptoms include dryness, burning, itching, dysuria, lichenoid manifestations, ulcers, up to genital fibrosis and vaginal occlusion that may lead to sexual dysfunctions and quality of life worsening.The use of peripherally collected blood progenitors were associated with higher risk of vv-cGvHD development.Vv-cGvHD is still largely under-recognized due to the paucity of high quality studies, that frequently included selection biases, and to patientsrelated issues, including social and cultural aspects.Methods: An observational, prospective, monocentric, noninterventional study has been ongoing since October 2019.Aim of the study was to assess the local incidence of vv-cGvHD in adult women admitted in our transplant unit.Secondary objective was to detect any associations of vv-cGvHD with GvHD manifestations in other organs.The assessment of patients' vaginal conditions was organized in 4 gynecological visits at baseline (T0) before HSCT, at day +100 (T1), +180 (T2) and at 1 year after transplant (T3).The questionnaire of the Swedish Society of Obstetrics and Gynecology (SSOG) for females with vulvo-vaginal problems was administered during the visits to collect patient reported outcomes (PROs).This study was approved by the local ethic committee.Results: Twenty-four consecutive patients were recruited at the time of this abstract.All but one received one allo-HSCT.Median age was 49 years (range 20-69 years).Diagnoses included acute leukemia (n = 18), lymphoma (n = 5), and chronic myelomonocytic leukemia (n = 1).Eleven patients (46%) received a myeloablative conditioning, 14 (58.4%) were transplanted from unrelated, 8 (33.3%) from haplo and 2 (8.3%) from sibling donors; almost all (91.7%) received peripheral stem cells.Acute GvHD was observed in 8 (33%) patients: 4 skin, 3 gastrointestinal and 1 both.Chronic GvHD without genital symptoms was found in 7 patients (29.2%), 6 mild skin and/or gut cGvHD and 1 with moderate/severe manifestations.In the whole cohort of patients, 5 (20.8%) reported genital problems without clinical signs of vv-cGvHD and 6 women (25.0%) developed vv-cGvHD, with a median onset time at day +100.According to NIH criteria 4 patients had grade 1 vv-cGvHD (dryness, dystrophy) and 2 patients had grade 2 vv-cGvHD (lichen planus).Four patients with vv-cGvHD developed systemic c-GvHD:2 patients mild skin, 1 mild skin/ocular/liver, 1 moderate oral/skin.Conclusions: The incidence of vv-cGvHD in our cohort was in line with literature data.Our study confirms that vv-cGvHD is an important and under-recognized complication of allogeneic SCT with the potential to impair quality of life and sexual function.Therefore, considering that most patients diagnosed with vv-cGvHD had no symptoms, we recommend to include routine gynecology visits in monitoring protocols of female patients submitted to allogeneic transplant.